Impact of Switching to Continuous Release Dopamine Agonists
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this proposal is to determine if switching PD patients treated with
pramipexole to ropinirole CR reduces the non-motor side effects frequently experienced by
these patients. Side effects that we will monitor in particular include somnolence,
peripheral edema, cognitive decline with and without hallucinations. PD patients followed in
the MUO Neurology Clinic who are being treated with pramipexole and have evidence of at least
one of the following symptoms: somnolence, cognitive impairment with or without
hallucinations, or peripheral edema will be offered the opportunity to participate in this
study.